Journal article

Neurologic complications of influenza A(H1N1)pdm09 Surveillance in 6 pediatric hospitals

Gulam Khandaker, Yvonne Zurynski, Jim Buttery, Helen Marshall, Peter C Richmond, Russell C Dale, Jenny Royle, Michael Gold, Tom Snelling, Bruce Whitehead, Cheryl Jones, Leon Heron, Mary McCaskill, Kristine Macartney, Elizabeth J Elliott, Robert Booy

Neurology | LIPPINCOTT WILLIAMS & WILKINS | Published : 2012


Awarded by National Health and Medical Research Council (NHMRC) H1N1

Awarded by NHMRC

Awarded by NHMRC Career Development Fellowship

Funding Acknowledgements

This project was funded in part by the NSW Department of Health and the National Health and Medical Research Council (NHMRC) H1N1 grant no: 633028. Activities of the APSU and NCIRS are supported by the Australian Government Department of Health and Ageing. APSU is supported by the NHMRC (enabling grant no.: 402784 and practitioner fellowship no.: 457084, E. Elliott); the Creswick Foundation (fellowship: Y. Zurynski); NHMRC Career Development Fellowship (no. 1016272: H. Marshall); the Discipline of Paediatrics and Child Health and Faculty of Medicine, University of Sydney; the Children's Hospital at Westmead; and the Royal Australasian College of Physicians.G. Khandaker is an investigator in studies supported by Roche and National Health and Medical Research Council (NHMRC). Y. Zurynski reports no disclosures. J. Buttery has served on advisory and/or data safety monitoring committees for CSL Vaccines and GSK for which the Murdoch Children's Research Institute (MCRI) receives payments into an educational fund. MCRI has received travel support for J. B. to present scientific data at international meetings and he is an investigator in industry-sponsored vaccine trials. H. Marshall has participated as a board member of Global Advisory Boards for Merck, Novartis, and GlaxoSmithKline, has received travel support to present scientific data at international meetings, and is an Investigator in industry-sponsored clinical vaccine trials. P. C. Richmond is a member of the Vaccine Trials Group. The Vaccine Trials Group has received institutional funding for research from vaccine providers including CSL Biotherapies, Sanofi Pasteur, Baxter, and GlaxoSmithKline. Peter Richmond has also previously been a member of a CSL Limited vaccine advisory board and received travel support from Baxter and Pfizer to present scientific data at international meetings. R. C. Dale, J. Royle, M. Gold, T. Snelling, B. Whitehead, and C. Jones report no disclosures. L. Heron has performed consultancy work for Novartis for which payment was made to the National Centre for Immunisation Research and Surveillance. He has had travel expenses covered by GSK and has conducted sponsored research and investigator-driven research with funding from GSK, Wyeth, Merck, CSL, Roche, and Sanofi Pasteur. M. McCaskill, K. Macartney, and E. J. Elliott report no disclosures. R. Booy has received financial support from CSL, Sanofi, GSK, Roche, Novartis, and Wyeth, to conduct research and present at scientific meetings. Any funding received is directed to an NCIRS research account at The Children's Hospital at Westmead and is not personally accepted by Professor Booy. Go to for full disclosures.